Hospital‐Treated Infections and Risk of Disability Worsening in Multiple Sclerosis
Annals of Neurology · 2024-10 · 96 (4) · 694-703
DOI: 10.1002/ana.27026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 10.07.2024. Verfasst von Yihan Hu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Rituximab, Multiple Sclerosis, Glatiramer Acetate. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Swedish Research Council, Swedish Brain Fund, Vetenskapsrådet.
Abstract (Originalsprache)
Objective
To investigate the association between infections and disability worsening in people with multiple sclerosis (MS) treated with either B‐cell depleting therapy (rituximab) or interferon‐beta/glatiramer acetate (IFN/GA).
Methods
This cohort study spanned from 2000 to 2021, using data from the Swedish MS Registry linked to national health care registries, comprising 8,759 rituximab and 7,561 IFN/GA treatment episodes. The risk of hospital‐treated infection was estimated using multivariable Cox models. The association between infections and increase in Expanded Disability Status Scale (EDSS) scores was assessed using a doubly robust generalized estimating equations model. Additionally, a piece‐wise exponential model analyzed events of increased disability beyond defined cut‐off values, controlling for relapses, and MRI activity.
Results
Compared with IFN/GA, rituximab displayed increased risk of both inpatient‐ and outpatient‐treated infections (hazard ratio [HR], 2.08; 95% confidence interval [CI], 1.50–2.90 and HR, 1.37; 95% CI, 1.13–1.67, respectively). An inpatient‐treated infection was associated with a 0.19‐unit increase in EDSS (95% CI, 0.12–0.26). Degree of worsening was greatest for progressive MS, and under IFN/GA treatment, which unlike rituximab, was more commonly associated with MRI activity. After controlling for relapses and MRI activity, inpatient‐treated infections were associated with disability worsening in people with relapsing–remitting MS treated with IFN/GA (HR, 2.01; 95% CI, 1.59–2.53), but not in those treated with rituximab.
Interpretation
Compared to IFN/GA, rituximab doubled the infection risk, but reduced the risk of subsequent disability worsening. Further, the risk of worsening after hospital‐treated infection was greater with progressive MS than with relapsing–remitting MS. Infection risk should be considered to improve long term outcomes. ANN NEUROL 2024;96:694–703
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
- Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
- Med-X Center for Informatics, Sichuan University, Chengdu, China.
- West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, China.
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
ORCID-Profile: Yihan Hu, Thomas Frisell, Peter Alping, Huan Song, Fang Fang
Förderung
- Swedish Research Council
- Swedish Brain Fund
- Vetenskapsrådet
Zitieren
APA
Hu, Y., Frisell, T., Alping, P., Song, H., Pawitan, Y., Fang, F., & Piehl, F. (2024). Hospital‐Treated Infections and Risk of Disability Worsening in Multiple Sclerosis. Annals of Neurology, 96(4), 694-703. https://doi.org/10.1002/ana.27026
Vancouver
Hu Y, Frisell T, Alping P, Song H, Pawitan Y, Fang F, et al. Hospital‐Treated Infections and Risk of Disability Worsening in Multiple Sclerosis. Annals of Neurology. 2024;96(4):694-703. doi:10.1002/ana.27026
BibTeX
@article{Hu2024,
author = {Hu, Yihan and Frisell, Thomas and Alping, Peter and Song, Huan and Pawitan, Yudi and Fang, Fang and Piehl, Fredrik},
title = {Hospital‐Treated Infections and Risk of Disability Worsening in Multiple Sclerosis},
journal = {Annals of Neurology},
year = {2024},
volume = {96},
number = {4},
pages = {694--703},
doi = {10.1002/ana.27026}
}
EUVIMED